BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Williams JG, Alam MF, Alrubaiy L, Arnott I, Clement C, Cohen D, Gordon JN, Hawthorne AB, Hilton M, Hutchings HA, Jawhari AU, Longo M, Mansfield J, Morgan JM, Rapport F, Seagrove AC, Sebastian S, Shaw I, Travis SP, Watkins A. Infliximab vs ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomized trial. Lancet Gastroenterol Hepatol. 2016;1:15-24. [PMID: 27595142 DOI: 10.1016/s2468-1253(16)30003-6] [Cited by in Crossref: 108] [Cited by in F6Publishing: 36] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Glaysher MA, Mohanaruban A, Prechtl CG, Goldstone AP, Miras AD, Lord J, Chhina N, Falaschetti E, Johnson NA, Al-Najim W, Smith C, Li JV, Patel M, Ahmed AR, Moore M, Poulter N, Bloom S, Darzi A, Le Roux C, Byrne JP, Teare JP. A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. BMJ Open 2017;7:e018598. [PMID: 29146657 DOI: 10.1136/bmjopen-2017-018598] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
2 Bonovas S, Pansieri C, Piovani D, Macaluso FS, Orlando A, Festa S, Papi C, Pugliese D, Armuzzi A. Use of biologics and small molecule drugs for the management of moderate to severe ulcerative colitis: IG-IBD technical review based on the GRADE methodology. Dig Liver Dis 2022:S1590-8658(22)00134-7. [PMID: 35183439 DOI: 10.1016/j.dld.2022.01.123] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Ng SC, Mak JWY, Pal P, Banerjee R. Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia. Lancet Gastroenterol Hepatol 2020;5:1089-100. [PMID: 33181088 DOI: 10.1016/S2468-1253(20)30298-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Formica RN, Turgeon N. It Is Time for Patient-Reported Outcome Measures to Be Included in the Approval Process for Solid Organ Transplant Medications. JASN 2021;32:2984-6. [DOI: 10.1681/asn.2021081136] [Reference Citation Analysis]
5 Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020;17:365-76. [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
6 Viscido A, Papi C, Latella G, Frieri G. Has infliximab influenced the course and prognosis of acute severe ulcerative colitis? Biologics 2019;13:23-31. [PMID: 31114154 DOI: 10.2147/BTT.S179006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
7 Patel P, Yarur A, Dalal S, Sakuraba A, Rubin DT, Hanauer SB, Hanan I, Raffals LH, Cohen RD, Pekow J. Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy. Inflamm Bowel Dis 2018;24:1291-7. [PMID: 29506124 DOI: 10.1093/ibd/izx105] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
8 Nalagatla N, Falloon K, Tran G, Borren NZ, Avalos D, Luther J, Colizzo F, Garber J, Khalili H, Melia J, Bohm M, Ananthakrishnan AN. Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clin Gastroenterol Hepatol 2019;17:502-509.e1. [PMID: 29944926 DOI: 10.1016/j.cgh.2018.06.031] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
9 Xiao Y, Benoit N, Sedano R, Jairath V, Narula N, McCurdy JD, Rosenfeld G, Afif W, Lakatos PL, Bessissow T. Effectiveness of Tofacitinib for Hospitalized Patients with Acute Severe Ulcerative Colitis: Case Series. Dig Dis Sci 2022. [PMID: 35244825 DOI: 10.1007/s10620-022-07439-2] [Reference Citation Analysis]
10 Sebastian S, Patel KV, Segal JP, Subramanian S, Conley TE, Gonzalez HA, Kent AJ, Saifuddin A, Hicks L, Mehta S, Bhala N, Brookes MJ, Lamb CA, Kennedy NA, Walker GJ; PROTECT ASUC collaborators. Ambulatory care management of 69 patients with acute severe ulcerative colitis in comparison to 695 inpatients: insights from a multicentre UK cohort study. BMJ Open Gastroenterol 2022;9:e000763. [DOI: 10.1136/bmjgast-2021-000763] [Reference Citation Analysis]
11 Choy MC, De Cruz P. Letter: dose optimising infliximab in acute severe ulcerative colitis. Aliment Pharmacol Ther 2017;45:1169-70. [PMID: 28326583 DOI: 10.1111/apt.13980] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Forbes A. Immunosuppressants and immune modulators in luminal gastroenterology. Best Pract Res Clin Gastroenterol 2021;54-55:101759. [PMID: 34874843 DOI: 10.1016/j.bpg.2021.101759] [Reference Citation Analysis]
13 McDonnell M, Harris RJ, Borca F, Mills T, Downey L, Dharmasiri S, Patel M, Zare B, Stammers M, Smith TR, Felwick R, Cummings JRF, Phan HTT, Gwiggner M. High incidence of glucocorticoid-induced hyperglycaemia in inflammatory bowel disease: metabolic and clinical predictors identified by machine learning. BMJ Open Gastroenterol 2020;7:e000532. [PMID: 33187976 DOI: 10.1136/bmjgast-2020-000532] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
14 Dulai PS, Jairath V. A Microsimulation Model to Project the 5-Year Impact of Using Hyperbaric Oxygen Therapy for Ulcerative Colitis Patients Hospitalized for Acute Flares. Dig Dis Sci 2021;66:3740-52. [PMID: 33185788 DOI: 10.1007/s10620-020-06707-3] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:56-66. [PMID: 29889235 DOI: 10.1093/ibd/izy208] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
16 Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C, Barrett KJ, Davies RJ, Bennett C, Gittens S, Dunlop MG, Faiz O, Fraser A, Garrick V, Johnston PD, Parkes M, Sanderson J, Terry H, Gaya DR, Iqbal TH, Taylor SA, Smith M, Brookes M, Hansen R, Hawthorne AB; IBD guidelines eDelphi consensus group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1-s106. [PMID: 31562236 DOI: 10.1136/gutjnl-2019-318484] [Cited by in Crossref: 617] [Cited by in F6Publishing: 451] [Article Influence: 205.7] [Reference Citation Analysis]
17 Siegmund B. Janus Kinase inhibitors in the New Treatment Paradigms of Inflammatory Bowel Disease. J Crohns Colitis 2020;14:S761-6. [PMID: 31922534 DOI: 10.1093/ecco-jcc/jjaa003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Sebastian S, Lisle J, Subramanian S, Dhar A, Shenoy A, Limdi J, Butterworth J, Allen PB, Samuel S, Moran G, Shenderey R, Parkes G, Raine T, Lobo AJ, Kennedy NA. Practice pattern variability in the management of acute severe colitis: a UK provider survey. Frontline Gastroenterol 2020;11:272-9. [PMID: 32587670 DOI: 10.1136/flgastro-2019-101277] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
19 Grazie ML, Bagnoli S, Dragoni G, Caini S, Annese V, Innocenti T, Deiana S, Manetti N, Milani S, Galli A, Milla M. Infliximab is more effective than cyclosporine as a rescue therapy for acute severe ulcerative colitis: a retrospective single-center study. Ann Gastroenterol 2021;34:370-7. [PMID: 33948062 DOI: 10.20524/aog.2021.0584] [Reference Citation Analysis]
20 Sebastian S, Myers S, Nadir S, Subramanian S. Systematic Review: Efficacy and Safety of Accelerated Induction Regimes in Infliximab Rescue Therapy for Hospitalized Patients with Acute Severe Colitis. Dig Dis Sci. 2019;64:1119-1128. [PMID: 30535888 DOI: 10.1007/s10620-018-5407-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
21 Clement C, Rapport F, Seagrove A, Alrubaiy L, Williams J. Healthcare professionals' views of the use and administration of two salvage therapy drugs for acute ulcerative colitis: a nested qualitative study within the CONSTRUCT trial. BMJ Open 2017;7:e014512. [PMID: 28399515 DOI: 10.1136/bmjopen-2016-014512] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ghouri YA, Tahan V, Shen B. Secondary causes of inflammatory bowel diseases. World J Gastroenterol 2020; 26(28): 3998-4017 [PMID: 32821067 DOI: 10.3748/wjg.v26.i28.3998] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
23 Fehily SR, Martin FC, Kamm MA. Simple water-based tacrolimus enemas for refractory proctitis. JGH Open 2020;4:561-4. [PMID: 32782938 DOI: 10.1002/jgh3.12280] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
24 Touray MML. Estimation of Quality-adjusted Life Years alongside clinical trials: the impact of 'time-effects' on trial results. J Pharm Health Serv Res 2018;9:109-14. [PMID: 29861785 DOI: 10.1111/jphs.12218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Leake I. IBD: Treatment for acute severe ulcerative colitis. Nat Rev Gastroenterol Hepatol 2016;13:436. [PMID: 27407042 DOI: 10.1038/nrgastro.2016.112] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
26 Rosiou K, Selinger CP. Acute severe ulcerative colitis: management advice for internal medicine and emergency physicians. Intern Emerg Med 2021;16:1433-42. [PMID: 33754227 DOI: 10.1007/s11739-021-02704-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Yan X, Qiao Y, Tong J, Mao R, Liang J, Lv C, Chen Y, Wang Y, Shen J; Young Investigators for the study of Inflammatory Bowel Diseases (YIIBD). Assessment of patient-centered outcomes (PROs) in inflammatory bowel disease (IBD): a multicenter survey preceding a cross-disciplinary (functional) consensus. Health Qual Life Outcomes 2020;18:241. [PMID: 32690091 DOI: 10.1186/s12955-020-01489-8] [Reference Citation Analysis]
28 Hindryckx P, Jairath V, D'Haens G. Acute severe ulcerative colitis: from pathophysiology to clinical management. Nat Rev Gastroenterol Hepatol. 2016;13:654-664. [PMID: 27580687 DOI: 10.1038/nrgastro.2016.116] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 9.3] [Reference Citation Analysis]
29 Vitello D, Mcgee MF. Treatment of severe and fulminant colitis. Seminars in Colon and Rectal Surgery 2022. [DOI: 10.1016/j.scrs.2022.100864] [Reference Citation Analysis]
30 Segal JP, LeBlanc JF, Hart AL. Ulcerative colitis: an update. Clin Med (Lond) 2021;21:135-9. [PMID: 33762374 DOI: 10.7861/clinmed.2021-0080] [Reference Citation Analysis]
31 Holvoet T, Lobaton T, Hindryckx P. Optimal Management of Acute Severe Ulcerative Colitis (ASUC): Challenges and Solutions. Clin Exp Gastroenterol 2021;14:71-81. [PMID: 33727846 DOI: 10.2147/CEG.S197719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Feuerstein JD, Isaacs KL, Schneider Y, Siddique SM, Falck-Ytter Y, Singh S; AGA Institute Clinical Guidelines Committee. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology 2020;158:1450-61. [PMID: 31945371 DOI: 10.1053/j.gastro.2020.01.006] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 33.5] [Reference Citation Analysis]
33 O'Reilly C, O'Sullivan Ó, Cotter PD, O'Connor PM, Shanahan F, Cullen A, Rea MC, Hill C, Coulter I, Ross RP. Encapsulated cyclosporine does not change the composition of the human microbiota when assessed ex vivo and in vivo. J Med Microbiol 2020;69:854-63. [PMID: 31958048 DOI: 10.1099/jmm.0.001130] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
34 Singh S, Allegretti JR, Siddique SM, Terdiman JP. AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis.Gastroenterology. 2020;158:1465-1496.e17. [PMID: 31945351 DOI: 10.1053/j.gastro.2020.01.007] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 11.5] [Reference Citation Analysis]
35 Liu C, Mo LH, Feng BS, Jin QR, Li Y, Lin J, Shu Q, Liu ZG, Liu Z, Sun X, Yang PC. Twist1 contributes to developing and sustaining corticosteroid resistance in ulcerative colitis. Theranostics 2021;11:7797-812. [PMID: 34335965 DOI: 10.7150/thno.62256] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Thomas MG, Bayliss C, Bond S, Dowling F, Galea J, Jairath V, Lamb C, Probert C, Timperley-Preece E, Watson A, Whitehead L, Williams JG, Parkes M, Kaser A, Raine T. Trial summary and protocol for a phase II randomised placebo-controlled double-blinded trial of Interleukin 1 blockade in Acute Severe Colitis: the IASO trial. BMJ Open 2019;9:e023765. [PMID: 30772849 DOI: 10.1136/bmjopen-2018-023765] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
37 Glaysher MA, Mohanaruban A, Prechtl CG, Goldstone AP, Miras AD, Lord J, Chhina N, Falaschetti E, Johnson NA, Al-Najim W, Smith C, Li JV, Patel M, Ahmed AR, Moore M, Poulter N, Bloom S, Darzi A, Le Roux C, Byrne JP, Teare JP. A randomised controlled trial of a duodenal-jejunal bypass sleeve device (EndoBarrier) compared with standard medical therapy for the management of obese subjects with type 2 diabetes mellitus. BMJ Open 2017;7:e018598. [PMID: 29146657 DOI: 10.1136/bmjopen-2017-018598] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
38 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
39 Zhang M, Liu J, Liu T, Han W, Bai X, Ruan G, Lv H, Shu H, Li Y, Li J, Tan B, Zheng W, Xu H, Zheng W, Yang H, Qian J. The efficacy and safety of anti-tumor necrosis factor agents in the treatment of intestinal Behcet's disease, a systematic review and meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34894004 DOI: 10.1111/jgh.15754] [Reference Citation Analysis]
40 Festa S, Scribano ML, Pugliese D, Bezzio C, Principi M, Ribaldone DG, Allocca M, Mocci G, Bodini G, Spagnuolo R, Vernia P, Mazzuoli S, Costa F, Barberio B, Cosintino R, Zerboni G, Aratari A, Armuzzi A, Papi C. Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study. United European Gastroenterol J 2021;9:507-16. [PMID: 33259773 DOI: 10.1177/2050640620977405] [Reference Citation Analysis]
41 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
42 Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, Makharia GK, Pisespongsa P, Chen MH, Ran ZH, Ye BD, Park DI, Ling KL, Ong D, Ahuja V, Goh KL, Sollano J, Lim WC, Leung WK, Ali RAR, Wu DC, Ong E, Mustaffa N, Limsrivilai J, Hisamatsu T, Yang SK, Ouyang Q, Geary R, De Silva JH, Rerknimitr R, Simadibrata M, Abdullah M, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease and Asian Organization for Crohn’s and Colitis. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res 2019;17:285-310. [PMID: 31146509 DOI: 10.5217/ir.2019.00026] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 10.0] [Reference Citation Analysis]
43 Rapport F, Clement C, Seagrove AC, Alrubaiy L, Hutchings HA, Williams JG. Patient views about the impact of ulcerative colitis and its management with drug treatment and surgery: a nested qualitative study within the CONSTRUCT trial. BMC Gastroenterol 2019;19:166. [PMID: 31615445 DOI: 10.1186/s12876-019-1085-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
44 Conley TE, Fiske J, Subramanian S. How to manage: acute severe colitis. Frontline Gastroenterol 2022;13:64-72. [PMID: 34970430 DOI: 10.1136/flgastro-2020-101710] [Reference Citation Analysis]
45 Ganzleben I, Geppert C, Osaba L, Hirschmann S, Nägel A, Glück C, Hoffman A, Rath T, Nagore D, Neurath MF, Atreya R. Successful cyclosporin and ustekinumab combination therapy in a patient with severe steroid-refractory ulcerative colitis. Therap Adv Gastroenterol 2020;13:1756284820954112. [PMID: 33101457 DOI: 10.1177/1756284820954112] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
46 Weixler B, Sonnenberg E, Kreis ME. Colitis ulcerosa. coloproctology 2021;43:301-10. [DOI: 10.1007/s00053-021-00547-z] [Reference Citation Analysis]
47 Philippou A, Rizvi A, Steinlauf A. Dramatic Deep and Durable Remission of Acute Fulminant Ulcerative Colitis Achieved with Cyclosporine in a Patient Who Failed the Induction Intravenous Phase of Cyclosporine. Case Rep Gastroenterol 2021;15:147-53. [PMID: 33708063 DOI: 10.1159/000512426] [Reference Citation Analysis]
48 Weisshof R, Ollech JE, El Jurdi K, Yvellez OV, Cohen RD, Sakuraba A, Dalal S, Pekow J, Rubin DT. Ciclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe. J Crohns Colitis 2019;13:1105-10. [PMID: 30726894 DOI: 10.1093/ecco-jcc/jjz032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
49 Stansfield C. Considerations in the management of ulcerative colitis. Gastrointestinal Nursing 2016;14:42-50. [DOI: 10.12968/gasn.2016.14.7.42] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
50 Pellino G, Keller DS, Sampietro GM, Carvello M, Celentano V, Coco C, Colombo F, Geccherle A, Luglio G, Rottoli M, Scarpa M, Sciaudone G, Sica G, Sofo L, Zinicola R, Leone S, Danese S, Spinelli A, Delaini G, Selvaggi F; Italian Society of Colorectal Surgery SICCR. Inflammatory bowel disease position statement of the Italian Society of Colorectal Surgery (SICCR): ulcerative colitis. Tech Coloproctol 2020;24:397-419. [PMID: 32124113 DOI: 10.1007/s10151-020-02175-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
51 Tun GS, Harris A, Lobo AJ. Ulcerative colitis: management in adults, children and young people - concise guidance . Clin Med (Lond) 2017;17:429-33. [PMID: 28974592 DOI: 10.7861/clinmedicine.17-5-429] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
52 Choy MC, Seah D, Faleck DM, Shah SC, Chao CY, An YK, Radford-Smith G, Bessissow T, Dubinsky MC, Ford AC, Churilov L, Yeomans ND, De Cruz PP. Systematic Review and Meta-analysis: Optimal Salvage Therapy in Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019;25:1169-86. [PMID: 30605549 DOI: 10.1093/ibd/izy383] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]